亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients with Mild to Moderate Alzheimer’s Disease Treated with Donepezil: DHP1401 Randomized Trial in Mild to Moderate Alzheimer’s Disease (DRAMA)

耐受性 医学 临床终点 安慰剂 多奈哌齐 内科学 不利影响 随机对照试验 阿尔茨海默病 临床试验 胃肠病学 痴呆 疾病 病理 替代医学
作者
YongSoo Shim,Hyun Jeong Han,Kyung Won Park,Byeong C. Kim,Kee Hyung Park,Mee Young Park,Han Jo Kim,So Young Moon,Seong Hye Choi,Kun Woo Park,Dong Won Yang,Soo Jin Yoon,SangYun Kim,Young Chul Youn,Ho-Jin Choi,Koung Eun Yoon,Hyun-Ju Cho,Seol‐Heui Han
出处
期刊:Journal of Alzheimer's Disease [IOS Press]
卷期号:87 (1): 391-403 被引量:3
标识
DOI:10.3233/jad-215277
摘要

Background: Preclinical studies in transgenic models of Alzheimer’s disease (AD) suggest that DHP1401 has neuroprotective and memory-enhancing effects. Objective: To evaluate the efficacy and safety of DHP1401 in AD patients treated with donepezil Methods: Methods: In a double-blind study, patients with mild-to-moderate AD were randomized (1:1:1) to receive a twice daily total dose of 500 mg or 1000 mg DHP1401 or placebo for 24 weeks. Tolerability and safety were monitored at baseline and weeks 12 and 24. Results: total of 180 patients were randomized to Active 1 (500 mg: n = 62), Active 2 (1000 mg: n = 53), and control groups (n = 65) in 16 sites in Korea. There was no significant difference in the Alzheimer’s Disease Assessment Scale (ADAS-cog) score, the primary efficacy endpoint, from baseline. However, in the subgroup with mild AD patients (MMSE, 20–26) who received the high dose of DHP1401 and the group that received donepezil 5 mg, the ADAS-cog scores improved. MMSE and K-TMT-e type B were significant in both active groups at week 24. The most frequently observed symptom was dizziness (2.78%), and the most commonly observed reactions were related to metabolism and nutrition disorders (5.00%). No remarkable adverse events were observed for 24 weeks. Conclusion: Although the effectiveness of DHP1401 was not proved to be superior as the primary efficacy endpoint, the secondary endpoints, MMSE and K-TMT-e type B, showed significant beneficial effects. Also, the subgroups showed that ADAS-cog scores significantly were improved. DHP1401 could be proven beneficial for the AD treatment by further clinical trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
15秒前
Peiqi的应助被1874采纳,获得100
19秒前
farhad发布了新的文献求助10
20秒前
28秒前
petrichor发布了新的文献求助10
32秒前
syvshc的应助被宝石采纳,获得10
32秒前
大胆蛟凤完成签到,获得积分10
35秒前
48秒前
may发布了新的文献求助10
54秒前
1分钟前
五十二赫兹完成签到 ,获得积分10
1分钟前
1分钟前
大模型的应助被科研通管家采纳,获得10
1分钟前
1分钟前
高速公鹿发布了新的文献求助10
1分钟前
舒适刺猬完成签到 ,获得积分10
1分钟前
魏魏完成签到 ,获得积分10
1分钟前
旭旭完成签到,获得积分10
2分钟前
对白完成签到,获得积分10
2分钟前
ysh完成签到,获得积分10
2分钟前
林夕完成签到,获得积分10
3分钟前
3分钟前
和风完成签到 ,获得积分10
3分钟前
3分钟前
amiee发布了新的文献求助10
3分钟前
3分钟前
1874发布了新的文献求助30
3分钟前
3分钟前
穿肠酒发布了新的文献求助10
3分钟前
3分钟前
3分钟前
科研通AI6.3的应助被半亩月光采纳,获得10
3分钟前
魔幻初丹完成签到,获得积分10
3分钟前
3分钟前
佳佳发布了新的文献求助10
3分钟前
4分钟前
赘婿的应助被佳佳采纳,获得10
4分钟前
思美人兮君莫怀完成签到,获得积分10
4分钟前
4分钟前
搜集达人的应助被youli采纳,获得10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190117
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21852170
捐赠科研通 7788359
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2559994
邀请新用户注册赠送积分活动 2482862